Tuesday, March 31, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CMS Innovation Center launches initiative to advance health equity

The Affordable Care Act created the Center for Medicare & Medicaid Innovation (CMS Innovation Center) within the Centers for Medicare & Medicaid Services (CMS) to “test innovative payment and service delivery models to reduce program expenditures…while preserving or enhancing the quality of care furnished to individuals under” Medicare, Medicaid, and the Children’s Health Insurance Program (CHIP). Since its inception, we have launched more than 50 such innovative models—targeting specific health conditions, care episodes, provider types, and communities. From 2018 to 2020, an estimated 528,000 providers, serving more than 28 million Medicare, Medicaid, and CHIP beneficiaries, participated in these models.

In 2021, after the CMS Innovation Center’s first ten years in existence, we conducted an in-depth performance review, and equity was one area of focus. Health equity is defined by CMS as “the attainment of the highest level of health for all people, where everyone has a fair and just opportunity to attain their optimal health regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, preferred language, or other factors that affect access to care and health outcomes.”

 

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!